rivastigmine 3 MG Oral Capsule
1 INDICATIONS AND USAGE Rivastigmine tartrate capsules are an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) ( 1.1 ) Mild-to-moderate dementia associated with Parkinson’s disease (PD) ( 1.2 ) 1.1 Alzheimer’s Disease Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson’s Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).
Actavis Pharma, Inc.
CAPSULE YELLOW WATSON 3209
Related Pills
rivastigmine 1.5 MG Oral Capsule
Actavis Pharma, Inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Rivastigmine Tartrate capsules USP equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of rivastigmine base are available as follows: 1.5 mg – Hard gelatin capsules with orange opaque cap and body printed with WATSON over 3208 on both cap and body in black ink. capsules are supplied in bottles of 60 (NDC 0591-3208-60). 3 mg - Hard gelatin capsules with yellow opaque cap and body printed with WATSON over 3209 on both cap and body in black ink. capsules are supplied in bottles of 60 (NDC 0591-3209-60). 4.5 mg - Hard gelatin capsules with light brown opaque cap and body printed with WATSON over 3210 on both cap and body in black ink. capsules are supplied in bottles of 60 (NDC 0591-3210-60). 6 mg - Hard gelatin capsules with light brown opaque cap and orange opaque body printed with WATSON over 3211 on both cap and body in black ink.capsules are supplied in bottles of 60 (NDC 0591-3211-60). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
More pills like CAPSULE WATSON 3209